Arcus Biosciences (NYSE:RCUS) said on Thursday that its experimental drug candidate, quemliclustat, has received orphan drug status from the U.S. FDA.

Quemliclustat is a type of medication that works by blocking a specific protein involved in cancer growth. This drug is